Trial Profile
A Double-blind, Placebo Controlled, Cross-over Renal Mechanistic Trial to Assess the Effect of Adding Empagliflozin Versus Placebo on Renal Hyperfiltration on a Background of the Angiotensin Converting Enzyme Inhibitor (ACEi) Ramipril: BETWEEN Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms BETWEEN
- Sponsors Boehringer Ingelheim
- 11 Jul 2022 According to Results published in the Circulation, recruitment was stopped early because of an unexpectedly low proportion of patients with hyperfiltration.
- 11 Jul 2022 Primary endpoint (Change in glomerular filtration rate (GFR) after treatment with either empagliflozin added to ramipril or placebo added to ramipril.) has been met, according to Results published in the Circulation.
- 11 Jul 2022 Results published in the Circulation